American Journal of Nephrology
Clinical Study
A New Treatment forInterdialytic Hyperkalemia – The Use of Fosinopril SodiumMousa D. · Rassoul Z. · Popovich W. · Hassan A. · Margate V. · Hawas F. · Suleiman M. · Al Khader A.Department of Nephrology, Riyadh Military Hospital, Riyadh, Saudi Arabia
Keywords: FosinoprilHemodialysisHyperkalemia |
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: June 18, 1999
Issue release date: May – June
Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 2
ISSN: 0250-8095 (Print)
eISSN: 1421-9670 (Online)
For additional information: https://www.karger.com/AJN
Abstract
Fosinopril sodium is the first of the phosphinic acid class of angiotensin-converting enzyme inhibitors (ACEI). It is used as an antihypertensive agent, but differs from other ACEI in its dual routes of excretion (liver and kidney), and less incidence of hyperkalemia and cough. We conducted a study in known chronic hemodialysis patients who developed interdialytic hyperkalemia in spite of other treatments to control hyperkalemia. We used fosinopril in this group of patients to assess the effect of fosinopril on serum potassium (K) levels. Twenty-four patients were given fosinopril 10 mg at 18:00 h daily for 8 weeks. K levels were measured before and after each dialysis treatment. Interdialytic weight gains were recorded. The average pretrial potassium level was 6.57 mmol/l (± 0.47), and the posttrial level was 5.34 (± 0.76); p ≤ 0.0001. No statistically significant interdialytic weight gain or reduction occurred. No first dose hypertensive effect or cough were reported. We have found the use of fosinopril to be successful in lowering predialysis serum K levels in hyperkalemic dialysis patients.
Related Articles:
References
- Singhvi SM, Duchin KL, Morrison RA, Williard DA, Everett DW, Frantz M: Disposition of fosinopril sodium in healthy subjects. Br J Clin Pharmacol 1988;25:9–15.
-
Duchin KL: Clinical pharmacology of fosinopril. Drug Invest 1995;3(suppl 4):12–17.
-
Germino FW, Lastra J, Pool P, Punzi H, Spinowitz B, Smith W, Mills D: An open label pilot study evaluating cough profile of fosinopril sodium in hypertensive patients with documented cough associated with previous ACE inhibitor monotherapy (abstract). Am J Hypertens 1992;6:113A.
- David D, Jallad N, Germino W, Willett M, de Silva J, Weidner S, Mills D: A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with a history of ACE inhibitor-associated cough. Am J Ther 1995;2:806–813.
-
Duchin KL, Kripalani K, Kramer P, Sica D: Disposition and pharmacodynamics of fosinopril sodium and its diacid in hemodialysis patients (abstract). Kidney Int 1989;35:245.
-
Sica D, Davis J, Fakhry I, Nunley J: Fosinopril sodium pharmacokinetic and pharmacodynamics in CAPD (abstract). Kidney Int 1989;35:277.
- Textor SC, Bravo EL, Fouad FM, Terazi RC: Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med 1982;73:719–725.
- Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN: Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention, and natriuresis. Hypertension 1979;1:274–280.
- Mulrow PJ, Kusano E, Baba K, Shier D, Doi Y: Adrenal renin: A possible local hormonal regulator of aldosterone production. Yale J Biol Med 1989;62:503–510.
-
Schlueter W, Keilani T, Batlle DC: Tissue renin angiotensin systems: Theoretical implications for the development of hyperkalemia using angiotensin-converting enzyme inhibitors. Am J Med Sci 1994;307(suppl 1):81–86.
- Keilani T, Schlueter W, Batlle DC: Selected aspects of ACE inhibitor therapy for patients with renal disease: Impact on proteinuria, lipids and potassium. J Clin Pharmacol 1995;35:87–97.
-
Keilani T, Schlueter W, Molteni A, Batlle DC: Converting enzyme inhibition with fosinopril does not suppress plasma aldosterone and may not cause hyperkalemia despite moderate renal impairment. J Am Soc Nephrol 1991;2:281.
- Panese S, Martin R, Virginillo M: Mechanism of enhanced cellular potassium secretion in man with chronic renal failure. Kidney Int 1987;31:1377–1382.
-
Al Khader AA, Al Hasani MK, Dhar JM, Suleiman M: Effect of diet during Ramadan on patients on chronic hemodialysis. Saudi Med J 1991;12:30–31.
Article / Publication Details
Published online: June 18, 1999
Issue release date: May – June
Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 2
ISSN: 0250-8095 (Print)
eISSN: 1421-9670 (Online)
For additional information: https://www.karger.com/AJN
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
